InflaRx N.V. (NASDAQ:IFRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• InflaRx N.V. has received a consensus recommendation of "Moderate Buy" from six analysts, with five ratings for buy and one for sell.
• The average 12-month price target for InflaRx is set at $6.20, despite the company currently trading at approximately $1.58.
• Institutional investors own 42.39% of InflaRx's stock, with several hedge funds recently increasing their positions in the company.

Shares of InflaRx N.V. (NASDAQ:IFRX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the six analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $6.20.

A number of analysts have recently weighed in on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of InflaRx in a research report on Saturday, September 27th. HC Wainwright started coverage on shares of InflaRx in a report on Tuesday, September 2nd. They issued a "buy" rating and a $6.00 price objective for the company.

Hedge Funds Weigh In On InflaRx

Several hedge funds and other institutional investors have recently modified their holdings of IFRX. 683 Capital Management LLC raised its position in InflaRx by 26.8% in the first quarter. 683 Capital Management LLC now owns 2,625,000 shares of the company's stock worth $2,678,000 after acquiring an additional 555,000 shares in the last quarter. Woodline Partners LP bought a new stake in InflaRx in the first quarter worth about $766,000. DAFNA Capital Management LLC bought a new stake in InflaRx in the first quarter worth about $459,000. Adage Capital Partners GP L.L.C. bought a new stake in InflaRx in the second quarter worth about $262,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in InflaRx by 158.3% in the second quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company's stock worth $118,000 after acquiring an additional 91,927 shares in the last quarter. Institutional investors and hedge funds own 42.39% of the company's stock.

InflaRx Price Performance

NASDAQ IFRX traded up $0.20 during mid-day trading on Friday, hitting $1.58. The company's stock had a trading volume of 602,024 shares, compared to its average volume of 463,707. InflaRx has a 52-week low of $0.71 and a 52-week high of $2.82. The stock's fifty day simple moving average is $1.16 and its two-hundred day simple moving average is $1.13. The firm has a market capitalization of $106.07 million, a P/E ratio of -1.97 and a beta of 1.40.

InflaRx (NASDAQ:IFRX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.24). The firm had revenue of $0.05 million for the quarter, compared to analysts' expectations of $0.02 million. On average, equities analysts forecast that InflaRx will post -1.04 earnings per share for the current fiscal year.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.